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resia: Is this the right one?
delay of 6 days from the ﬁrst evaluation (range 1–47 days). Only
three patients were not correctly diagnosed at the end of the ﬁrst
evaluation. One patient with BA was addressed to intraoperative
cholangiography with a delay of 47 days because cholestasis was
initially ascribed to the concomitant Hypothyroidism. Con-
versely, two newborns, which later received a diagnosis of
neonatal sclerosing cholangitis and non-syndromic ductal
paucity, respectively, underwent intraoperative cholangiography.
Liver histology was available for review in 27 cases, 16 from
needle biopsy and 11 from surgical biopsy. In this series of 27
patients, we retrospectively calculated the diagnostic score of
El-Guindi et al. at the time of ﬁrst evaluation. Mean age at ﬁrst
evaluation of the 27 infants was 60.4 days (range 29–122 days),
16 children had BA and 11 another cause of neonatal cholestasis
(3 transient neonatal cholestasis, 1 cystic ﬁbrosis, 1 neonatal
sclerosing cholangitis, 1 hypothyroidism, 2 non-syndromic
ductopenia, 1 mitochondrial depletion syndrome, 1 Niemann-
Pick type C, 1 biliary acids synthesis defect).
Clinical, histological and laboratory items were extracted from
medical records. A single radiologist (MPM) with speciﬁc experi-
ence in the ﬁeld [5], unaware of ﬁnal diagnosis, reviewed all
recorded ultrasound examinations, performed after six hours of
fasting, and calculated radiological items. Among them, only gall-
bladder contractility was not possible to be evaluated from the
recorded images. This item was estimated comparing the ﬁrst
examination, performed after fasting, with other tests performed
randomly in the following days. At least one follow-up ultra-
sound was available for all patients. Prevalence of single items
of the score is showed in Table 1. Global sensitivity was 31%
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To the Editor:
We read with interest the recent article by El-Guindi et al. [1].
An effective bedside diagnostic score for biliary atresia (BA) in
cholestatic infants, despite decades of clinical experience, is still
lacking, and none of the few proposed in the past achieved a
widespread application in clinical practice [2–4]. The task is
tough; the perfect score should fulﬁll two conﬂicting require-
ments. Despite the great clinical heterogeneity, a near 100%
sensitivity is mandatory because of the time-dependent surgical
treatment. On the other hand, invasive procedures, such as intra-
operative cholangiography or liver biopsy, should be avoided as
much as possible in very small children.
Starting from state-of-the-art knowledge about all previously
reported signs of BA, El-Guindi et al. formulated a new twelve-
point diagnostic score using a smart statistical approach. Subse-
quent validation on a cohort of 75 consecutive patients showed
an overall high diagnostic accuracy of 98% (sensitivity 100%,
speciﬁcity 97.6%). Because of such relevant results, we aimed to
challenge this scoring system with our historical series of
cholestatic newborns and compare results with those of our
current diagnostic protocol.
From January 2009, 64 patients were referred for neonatal
cholestasis. After initial assessment, including clinical evaluation,
ultrasound and targeted laboratory and/or radiological test to
rule out other deﬁnite diagnosis, 16 of them underwent liver
biopsy, 2 endoscopic retrograde cholangio-pancreatography,
and 18 intraoperative cholangiography. Sixteen newborns
received the diagnosis of BA and underwent Kasai procedure at
a median age of 62 days (range 34–128 days), with a medianJournal of Hepatology 2015 vol. 62 j 975–989 985
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(5/16), speciﬁcity 90.9% (10/11), positive predictive values was
0.81 and negative predictive values 0.47. Overall diagnostic
accuracy resulted 0.55.
Reasons for such disappointing results might be numerous.
First, the retrospective nature of this study is a major confound-
ing factor. A large, multicentric, prospectic study is needed to
validate this score. On the other hand, we believe that our group
of patients is quite different than the one used by authors to
validate the score. Our patients belong to a highly selected subset
of cholestatic infants, addressed even from reference centers for
invasive investigation. This new scoring system seems to work
poorly in this clinical setting, but the paradox is that an effective
score is typically needed in such kind of patients.
Children with a various combination of cholic stools, mild
cholestasis, known risk factors for transient cholestasis, normal
GGT activity and other features not suggestive of BA might be,
in most cases, effectively managed without the need of liver
histology as our results suggest. The overall performance of our
current protocol (3 diagnostic errors out of 64 cases), indeed, is
similar to that of this new scoring system, as claimed in the
paper. However, 48 liver biopsies were spared. Moreover, even
a large, prospective, collaborative study must include some kind
of selection criteria because it might not be ethical to propose a
liver biopsy to all children with ‘‘direct hyperbilirubinemia’’, as
stated in the paper, without further details.
In conclusion, waiting for results of prospective studies, we
believe that we are still waiting for an efﬁcacious and practical
clinical score for BA.
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Reply to: ‘‘A scoring system for biliary atresia: Is this the right one?’’
To the Editor:
We appreciate the interest of Sciveres and colleagues in our
recent study [1] and we would like to respond to their letter
and help them answer the question they raised. Looking thor-
oughly into their retrospective study, many limitations can be
easily pointed out and may account for their disappointment
and poor results. First, the retrospective nature of the study
was not the optimal approach for the validation of the biliary
atresia (BA) score. Second, the small number of patients
(n = 27) in their study carries a very low statistical power of
28.2% at an alpha of 0.05, 2-tailed with 95% CI. This intensiﬁes
the need for validation of the BA score on a sample size larger
than the one in the original article (n = 75) by El-Guindi et al.,
as we already suggested. Third, the historical data they collected
were not pre-designed to evaluate the score parameters before-
hand. For example, the gallbladder length before and after
Table 1. Prevalence of clinical, histological and laboratory items in relation to
the diagnostic score.
BA (n = 16) Non-BA (n = 11)
Clay stool 8 (50%) 1 (9%)
Triangular cord 2 (12.5%) 0
Contractile gallbladder 2 (12.5%) 5 (45.4%)
GL >20.5 mm 0 3 (27 %)
HAD >2.05 mm 4 (25%) 2 (18.2%)
HAD/PVD >0.445 mm 8 (50%) 5 (45.4%)
Hepatic subcapsular flow 1 (6%) 0
gGT >286 14 (87.5%) 6 (54.5 %)
PLT >349,000 11 (68.7%) 5 (45.4%)
DP 16 (100%) 6 (54.5 %)
BP 13 (81.2%) 3 (27 %)
GC 8 (50%) 3 (27 %)
GL, gallbladder length; HAD, hepatic artery diameter; PVD, portal vein diameter;
gGT, gamma glutamyl transpeptidase; PLT, platelets; DP, ductular proliferation;
BP, bile plugs; GC, giant cells.
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